McKesson Corporation (MCK), one of the largest U.S. pharmaceutical distributors and healthcare services companies, has spent 2026 climbing from a 52-week low near $724 to a 52-week high of $1,030.27, before settling at a latest close of $994.58 on October 30, 2026. The question facing investors is whether the stock can push through the next major psychological milestone: $1,100.
The $1,100 figure in the headline is not a published analyst consensus. Verified individual targets reviewed for this analysis cluster tightly just above the current price: Morgan Stanley raised its target to $1,207 (October 2026), UBS to $1,200, Leerink Partners to $1,070, Bank of America to $1,050, J.P. Morgan to $1,042, Mizuho to $1,020, TD Cowen to $1,006, and Barclays, Citi, and Evercore ISI to $1,000. Wells Fargo ($933) and RBC Capital ($845) sit at the cautious end. The arithmetic mean of roughly 16 targets is near $1,026, and the average of only the targets above the current price is about $1,060 — a figure still under the 10% threshold that would make it a meaningful 12-month objective. For that reason, $1,100 is presented as a round-number milestone, consistent with the upper portion of the Street's range, rather than as a consensus target.
At a latest close of $994.58, reaching $1,100 would require a gain of about 10.6% — a substantial move for a large-cap healthcare distributor with a beta near 0.30. McKesson trades at roughly 21–22 times forward earnings, below the market multiple for many growth names but a meaningful premium to the low end of its own history. The path toward the target would most plausibly run through sustained double-digit profit growth in oncology and specialty distribution, continued margin execution, and another round of positive earnings revisions after the company's next quarterly report.
McKesson reaffirmed fiscal 2027 adjusted EPS (earnings per share) guidance of $44.20 to $45.00 and a long-term adjusted EPS growth target of 13% to 16%. In its first fiscal quarter, revenue rose 8% to $105.4 billion and adjusted EPS climbed 20% to $9.93, with three segments posting double-digit profit growth. The company has raised its annual profit forecast on strength in its oncology and specialty drug businesses, and its roughly $2.25 billion acquisition of the Precision Medicine Group broadens oncology and biopharma capabilities. Strong free cash flow, active share repurchases, and a modest dividend (yield near 0.4%) provide additional ballast.
The distribution business carries thin margins — net margin is roughly 1.1% — so modest pricing, mix, or reimbursement pressure can have an outsized impact on earnings. McKesson also carries negative shareholders' equity, a structural balance-sheet feature that limits conventional financial flexibility, and its Medical-Surgical segment has shown weaker profit conversion. Healthcare policy and drug-pricing uncertainty, rising competition, and a valuation that has already expanded from the 52-week low of $723.68 represent additional headwinds. Any guidance cut or compression in the forward multiple would raise the bar for reaching $1,100.
McKesson's long-term trend remains firmly upward, with three-year and five-year total returns near 124% and 390%, respectively. In the near term, $1,000 is a key psychological level, and the 52-week high of $1,030.27 is the first meaningful resistance zone; $1,100 would be the next round-number objective beyond it. On the downside, support has formed near the recent $980 area and in the lower $900s.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms set their own timelines. McKesson reports second-quarter fiscal 2027 results on November 4, 2026, making that release the most immediate catalyst. Investors should also monitor guidance updates, analyst revisions, integration of the Precision Medicine Group and Option Care transaction, the MedSurg separation, healthcare policy developments, and broader interest-rate and sector-rotation trends.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing judgment, the tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently across a broad watchlist. For investors tracking a name like McKesson alongside hundreds of other securities, automating that daily screening can save time and surface changes worth a closer look.
Whether McKesson can reach $1,100 depends less on any single catalyst than on sustaining the specialty and oncology momentum that has driven recent beats, maintaining its 13%–16% EPS growth framework, and holding its premium valuation. The $1,100 milestone is not a consensus forecast — the analyst mean near $1,026 and the above-price average near $1,060 are both closer to current levels — but it sits within the upper portion of the Street's range and is a plausible round-number objective if execution continues. The November 4 earnings report and any subsequent guidance and target revisions will be the clearest signals of whether the required 10.6% advance is attainable. No outcome is guaranteed, and investors should weigh the company's growth record against its thin margins and structural balance-sheet risks.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MCK has been closely correlated with COR. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if MCK jumps, then COR could also see price increases.
| Ticker / NAME | Correlation To MCK | 1D Price Change % | ||
|---|---|---|---|---|
| MCK | 100% | -0.25% | ||
| COR - MCK | 70% Closely correlated | -0.14% | ||
| CAH - MCK | 66% Closely correlated | +0.25% | ||
| HKPD - MCK | 10% Poorly correlated | -5.00% | ||
| FOCL - MCK | 9% Poorly correlated | -3.40% | ||
| AHG - MCK | 7% Poorly correlated | -2.17% | ||
More | ||||